Navigation Links
Tax Specialty Firm McGuire Sponsel Urges Qualifying Biotech Companies to Apply for New Qualifying Therapeutic Discovery Project Credit Soon
Date:6/1/2010

INDIANAPOLIS, June 1 /PRNewswire/ -- Small- to mid-sized biotech companies can soon apply for a new tax incentive that allows them to claim a credit for 50 percent of their qualified investment in new medical technologies for tax years 2009 and 2010.

The Qualifying Therapeutic Discovery Project Credit is part of the Patient Protection and Affordable Care Act created by the Obama administration and signed into law in March. The bill states that qualified therapeutic discovery projects must involve activities that are designed to treat areas of unmet medical need. New technologies can also be designed to prevent, detect, treat and potentially cure chronic or acute diseases and conditions.

"The incentive will provide the capital these biotech companies need to further their research and development programs in hopes of creating new treatments, therapies and cures for disease," said TJ Sponsel, director at specialty tax firm McGuire Sponsel. "It is a great opportunity for qualifying companies but they have to act fast. Once the money is gone, it's gone."

Companies applying for the credit must submit applications from June 21 through July 21. The Internal Revenue Service will issue certifications by Oct. 29. Taxpayers must file a separate application for each qualified investment being pursued and qualified investments are capped at $10 million per taxpayer.

"Qualified investments include wages, supplies and lab costs, depreciable property, contractor costs and other development costs," Sponsel said. "There will be an emphasis placed on qualitative aspects of the research and experimentation focused on creating high-quality, high-paying jobs in the U.S. and advancing the country's overall competitiveness in the fields of life, biological and medical sciences."

All claims must be substantiated with supporting narratives, including a discussion of scientific rationale and evidence relied on for the project, a description of the nature of development of the project and a description of the resources, management experience and organizational capacity of the applicant. Congress has asked the treasury department to approve qualified applications within 30 days.

To learn more in-depth details and guidelines for applying for a Qualifying Therapeutic Discovery Project Credit, visit www.mcguiresponsel.com/biotech or call Sponsel at (317) 564-5002.


'/>"/>
SOURCE McGuire Sponsel
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
2. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
3. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
4. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
5. Diplomat Specialty Pharmacy Hires National Accounts Manager to Expand Multiple Sclerosis Program
6. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
7. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
8. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
9. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
10. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
11. A Perfect Storm Threatens Patient Access to Specialty Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) announced ... CEO and Fabrice Orecchioni, the company,s COO, has been named President, ... the past four years, Fabrice has overseen the construction, start-up and ... and the management of the Mitsui JV.  Fabrice has also been ... China JV. ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer diagnostics and pathology ... (Crosswalk), a unique precision medicine knowledge visualization and decision support platform. , ... diagnostic cockpit and is downloadable as an app for any mobile device and ...
(Date:2/20/2017)...  Former NFL players who had repeated head injuries may ... according to a preliminary study released today that will be ... in Boston , April 22 to 28, ... the muscles and nerves work together, like walking, kicking and ... ...
(Date:2/18/2017)... Kurzlehrgang mit Fokus auf Assay zum ... metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... Wie ... Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang zu ... intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der jährlich ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
Breaking Biology News(10 mins):